114214-49-2Relevant articles and documents
Synthesis and structure-activity relationship of 7-(3'-amino-4'-methoxypyrrolidin-1'-yl)-1-cyclopropyl-6,8-difluoro-1,4 -dihydro-4-oxoquinoline-3-carboxylic acids
Okada,Sato,Tsuji,Tsushima,Nakai,Yoshida,Matsuura
, p. 132 - 138 (1993)
A new series of quinolone derivatives 3a-l bearing 3-amino-4-methoxypyrrolidines of different configurations and chirality were synthesized and their antibacterial activities as well as some of their toxicological properties were examined. As predicted by our previous quantitative structure-activity relationships (QSAR) analysis of C-7 heterocyclic amine substituted quinolonecarboxylic acid antibacterial agents, these pyrrolidine derivatives showed higher in vitro and in vivo antibacterial activities against both gram-positive and gram-negative bacteria than the analogs bearing various 3-substituted azetidines. Furthermore, the amino and methoxy substituent groups on the pyrrolidine ring exhibited strong configurational and chiral effects on the in vitro and in vivo antibacterial activities of these compounds: (1) cis compounds showed higher antibacterial activities against most of the pathogens examined; (2) N-methylation of the 3-amino group on the pyrrolidine ring lowered in vitro but not in vivo antibacterial activities, particularly leading to superior in vivo anti-pseudomonal activity; (3) the (3'S,4'R)-derivative showed substantially higher activity that the (3'R,4'S)-one. These findings led to the selection of compound 3k for further evaluation as it possessed the highest in vivo antibacterial activity and no cytotoxicity.
Methyloxime-substituted aminopyrrolidine: A new surrogate for 7-basic group of quinolone
Hong, Chang Yong,Kim, Young Kwan,Lee, Yong Hee,Kwak, Jin Hwan
, p. 221 - 226 (1998)
Novel fluoroquinolones containing oxime functionalized aminopyrrolidines have been synthesized. They were found to possess potent antibacterial activities both Gram-negative and Gram-positive organisms, including methicillin resistant Staphylococcus aureus (MRSA). Among these compounds, LB20277 (compound 12) showed the most favorable in vivo efficacy and pharmacokinetic profile in animals. Based on these promising results, LB20277 was selected as a candidate for further evaluation.
JAK inhibitor compound and application thereof
-
Paragraph 0508; 0515; 0528-0530, (2020/09/12)
The invention relates to a JAK inhibitor compound and application thereof. Specifically, the invention discloses a compound shown as a formula (G), or an isotope labeled compound, or an optical isomer, a geometrical isomer, a tautomer or an isomer mixture of the compound, or a pharmaceutically acceptable salt of the compound, or a prodrug of the compound, or a metabolite of the compound. The invention also relates to the medical application of the compound.
Synthesis of new (±)-1-(4-(3-fluorobenzyloxy)pyrrolidin-3-yl)-4-phenyl-1H-1,2,3-triazole derivatives via click reaction and study of anti-cancer activity against HCT 116, MDA-MB231, Mia-PaCa2 cell lines
Kumar, Gollapudi Ravi,Murthy Boddapati,Meruga, Santha Kumari,Bollikolla, Hari Babu
, p. 2813 - 2825 (2020/10/06)
ASERIES of 16 new (±) -1-(4-(3-fluorobenzyloxy) pyrrolidin-3-yl)-4-phenyl-1H-1,2,3-triazole derivatives were synthesized from 2,5-dihydro-1H-pyrrole. Sixteen compounds are well characterized by their 1H NMR, 13C NMR and mass spectral data. Anticancer activities of these compounds were tested against HCT 116, MDA-MB231, Mia-PaCa2 cancer cell lines. Among these series of compounds, 8b exhibited highest activity with IC50 of 42.5 μg/ mL against MDA-MB231 cell line. The compound 8o and 8n showed moderate activity with IC50 of 64.3 μg/ mL and 68.4 μg/ mL against HCT -116 and Mia-PaCa2 cancer cell lines respectively.